Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$404K Sell
14,450
-24,327
-63% -$685K ﹤0.01% 10384
2026
Q1
$1.11M Buy
+38,777
New +$1.32M ﹤0.01% 7613
2025
Q3
Sell
-66,170
Closed -$2.28M 12345
2025
Q2
$2.17M Buy
66,170
+682
+1% +$22.2K ﹤0.01% 5623
2025
Q1
$2.11M Buy
65,488
+42,360
+183% +$1.57M ﹤0.01% 5409
2024
Q4
$707K Buy
23,128
+10,744
+87% +$346K ﹤0.01% 7804
2024
Q3
$347K Buy
+12,384
New +$305K ﹤0.01% 9283
2024
Q2
Sell
-76,533
Closed -$1.77M 12005
2024
Q1
$2.33M Buy
76,533
+31,419
+70% +$1.05M ﹤0.01% 4992
2023
Q4
$1.61M Buy
45,114
+33,973
+305% +$1.26M ﹤0.01% 5835
2023
Q3
$488K Sell
11,141
-28,698
-72% -$1.4M ﹤0.01% 8280
2023
Q2
$1.97M Buy
39,839
+19,229
+93% +$886K ﹤0.01% 5199
2023
Q1
$854K Buy
20,610
+9,815
+91% +$407K ﹤0.01% 7231
2022
Q4
$479K Sell
10,795
-2,769
-20% -$116K ﹤0.01% 7972
2022
Q3
$530K Buy
+13,564
New +$621K ﹤0.01% 8328
2022
Q1
Sell
-4,629
Closed -$322K 12942
2021
Q4
$322K Buy
+4,629
New +$336K ﹤0.01% 10304
2021
Q3
Sell
-8,199
Closed -$631K 12709
2021
Q2
$650K Buy
8,199
+4,337
+112% +$315K ﹤0.01% 8919
2021
Q1
$253K Sell
3,862
-5,884
-60% -$362K ﹤0.01% 10956
2020
Q4
$543K Buy
9,746
+4,527
+87% +$196K ﹤0.01% 8093
2020
Q3
$208K Buy
+5,219
New +$221K ﹤0.01% 9385
2020
Q2
Sell
-74,772
Closed -$3.26M 10096
2020
Q1
$2.51M Buy
+74,772
New +$2.69M ﹤0.01% 3569
2019
Q4
Sell
-23,547
Closed -$670K 9681
2019
Q3
$587K Buy
23,547
+9,512
+68% +$272K ﹤0.01% 6925
2019
Q2
$419K Sell
14,035
-26,840
-66% -$784K ﹤0.01% 7639
2019
Q1
$1.09M Buy
+40,875
New +$1.24M ﹤0.01% 4868
2017
Q1
Sell
-69,759
Closed -$1.22M 8907
2016
Q4
$1.36M Buy
+69,759
New +$1.26M ﹤0.01% 4870

Other funds holding ATRC

Jeff Yass's ATRC Position: Q2 2026 in Review

Jeff Yass reduced its AtriCure (ATRC) stake by 63% in Q2 2026, selling an estimated $685K and leaving 14,450 shares worth $404K. The position accounts for ﹤0.01% of the portfolio, ranked #10384.

Jeff Yass first reported a position in ATRC in Q4 2016 and has held it in 23 quarters since. The position peaked at $2.51M in Q1 2020. 250 funds tracked by Wall St. Rank hold ATRC as of Q2 2026.

  • Jeff Yass held 14,450 shares of AtriCure worth $404K as of Q2 2026.
  • Jeff Yass sold 24,327 AtriCure shares in Q2 2026, an estimated $685K.
  • AtriCure made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10384 holding.
  • Jeff Yass first reported a position in AtriCure in Q4 2016 and has held it in 23 quarters since.
  • Jeff Yass's AtriCure position peaked at $2.51M in Q1 2020.
  • 250 funds tracked by Wall St. Rank held AtriCure as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.